Top Markets
#1 Black Phoenix Black Phoenix +356.02%
#2 Glidr Glidr +84.34%
#3 Gold Park Gold Park +56.21%
#4 Akedo Akedo +46.51%
#5 Acurast Acurast +34.08%
#6 FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock) +26.76%
#7 BasedHype BasedHype +25.78%
#8 Avantis Avantis +23.46%
#9 Cryptopia Cryptopia +21.54%
#10 Quantum Resistant Ledger Quantum Resistant Ledger +16.54%
Coin of the day
Black Phoenix Black Phoenix
Instellingen
Taal
DUTCH
Valuta
USD
Thema
Histogen Inc. Histogen Inc.

Histogen Inc.

HSTO
Rang in aandelen #40870
Histogen Inc. operates as a clinical-stage biotechnology company, focusing on... Histogen Inc. operates as a clinical-stage biotechnology company, focusing on the development of novel, stem cell-free biologic products derived from its proprietary hypoxia-generated growth factor technology platform. Among its offerings is HST-003, a human extracellular matrix, currently undergoing Phase 1/2 clinical trials to mend articular cartilage defects in the knee. Additionally, the company is advancing HST-004, a cell-conditioned media solution designed for spinal disc repair, and Emricasan, an orally active pan-caspase inhibitor targeting COVID-19 treatment. In its preclinical pipeline, Histogen is developing CTS-2090 and CTS-2096. These are selective caspase-1 inhibitors formulated to suppress inflammasome activation and intervene in a range of inflammation-mediated conditions. Founded in 2007, Histogen Inc. maintains its headquarters in San Diego, California.
Aandeelprijs
$0.02765
Laatst gesynchroniseerd: 2024-12-23
Marktkapitalisatie
$69.04K
Verandering (1 dag)
0.00%
Verandering (1 jaar)
0.00%
Land
US
Handel Histogen Inc. (HSTO)

Categorie

Healthcare
Winst voor Histogen Inc. (HSTO)
Winst in Sep 2023 TTM: $-12.38M
Volgens de meest recente financiële verslagen van Histogen Inc. bedraagt de huidige winst van het bedrijf $-12.38M. In 2021 behaalde het bedrijf een winst van $-15.01M, een stijging ten opzichte van de winst van 2020, die $-18.82M bedroeg. De weergegeven winst op deze pagina is de winst vóór rente en belastingen, oftewel EBIT.
Winstgeschiedenis van Histogen Inc. van 2011 tot 2026
Winst aan het einde van elk jaar
Jaar Winst Wijzigen
2026 (TTM) $-12.38M 16.35%
2022 $-10.64M -29.08%
2021 $-15.01M -20.24%
2020 $-18.82M 65.28%
2019 $-11.39M -36.79%
2018 $-18.01M 3.53%
2017 $-17.40M -41.49%
2016 $-29.73M 23.12%
2015 $-24.15M 8.19%
2014 $-22.32M 42.93%
2013 $-15.62M 78.48%
2012 $-8.75M -27.07%
2011 $-12.00M 0.00%
Winst van vergelijkbare bedrijven of concurrenten
Bedrijf Winst Winstverschil Land
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
$5.27B -42,694.48%
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
$1.95B -15,851.37%
NL
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
- -
CH
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd.
207940.KS
- -
KR
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
$3.01B -24,370.97%
BE